CLRB — Cellectar Biosciences, Inc.

Cellectar Biosciences Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: Ended Q1 2026 with approximately $8.3 million in cash and cash equivalents, down from $13.2 million at the end of 2025.
• R&D Expenses: Approximately $3 million, a decrease from $3.4 million in Q1 2025, attributed to reduced follow-up activities and preclinical development.
• G&A Expenses: $2.8 million, slightly down from $3 million in the same period last year.
• Net Loss: Reported a net loss of $5.7 million ($1.33 per share), improved from a loss of $6.6 million ($4.30 per share) in Q1 2025.
• Financing: Completed an oversubscribed financing of up to $140 million, including $35 million upfront and up to $105 million based on milestones.

2. Strategic Updates and Business Highlights

• Clinical Progress: Positive 12-month follow-up data from the Phase IIb CLOVER WaM study for iopofosine I 131 in relapsed/refractory Waldenstrom Macroglobulinemia (WM) demonstrated an overall response rate of 83.6% and a median duration of response of 17.8 months.
• Regulatory Plans: Plans to file for accelerated approval with the FDA and initiate a randomized Phase III confirmatory trial for iopofosine.
• Pipeline Development: Dosing of first patients in the Phase Ib trial of CLR125 for triple-negative breast cancer (TNBC) has commenced, with promising preclinical data supporting its potential efficacy.

3. Forward Guidance and Outlook

• Phase III Trial: Anticipated initiation of the Phase III trial for iopofosine in late Q4 2026, with a focus on progression-free survival as the primary endpoint.
• NDA Submission: Expected to submit a New Drug Application (NDA) under accelerated approval in the second half of 2027, following the initiation of the Phase III study.
• Financial Stability: The recent financing strengthens the balance sheet, enabling continued development and operational funding through at least Q2 2027.

4. Bad News, Challenges, or Points of Concern

• Cash Burn: The decrease in cash reserves from the previous year raises concerns about operational sustainability without the recent financing.
• Clinical Risks: The success of the Phase III trial and subsequent NDA submission is contingent on meeting regulatory expectations and achieving positive clinical outcomes.
• Market Competition: The competitive landscape for WM treatments remains challenging, particularly with existing therapies and potential new entrants.

5. Notable Q&A Insights

• Patient Transition: Over 50% of patients in the CLOVER WaM study transitioned directly from BTK inhibitors to iopofosine, with common prior therapies including rituximab.
• Comparator Arm for Phase III: The planned comparator arm for the Phase III trial is rituximab, cyclophosphamide, and dexamethasone (RCD), with expected progression-free survival rates for the control arm ranging from 5.8 to 8.1 months based on historical data.
• NDA Timeline: The timeline for NDA submission is closely tied to the initiation of the Phase III trial, with expectations for FDA action within six months of submission, potentially leading to approval in the second half of 2027.

Overall, Cellectar Biosciences is positioned for significant clinical and financial developments in 2026, with a focus on advancing its promising pipeline while navigating inherent risks and competition in the oncology market.